Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography
Journal of Cardiovascular Ultrasound
;
: 1-25, 2018.
Article
in English
| WPRIM
| ID: wpr-713245
ABSTRACT
Cardiovascular (CV) toxicity associated with anti-cancer treatment is commonly encountered and raises critical problems that often result in serious morbidity or mortality. Most cardiac toxicities are related to the cumulative dose of chemotherapy; however, the type of chemotherapy, concomitant agents, and/or conventional CV risk factors have been frequently implicated in CV toxicity. Approximately half of the patients exhibiting CV toxicity receive an anthracycline-based regimen. Therefore, serologic biomarkers or cardiac imagings are important during anti-cancer treatment for early detection and the decision of appropriate management of cardiotoxicity. However, given the difficulty in determining a causal relationship, a multidisciplinary collaborative approach between cardiologists and oncologists is required. In this review, we summarize the CV toxicity and focus on the role of cardiac imaging in management strategies for cardiotoxicity associated with anti-cancer treatment.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Echocardiography
/
Biomarkers
/
Risk Factors
/
Mortality
/
Diagnosis
/
Drug Therapy
/
Cardiotoxicity
Type of study:
Diagnostic study
/
Etiology study
/
Prognostic study
/
Risk factors
/
Screening study
Limits:
Humans
Language:
English
Journal:
Journal of Cardiovascular Ultrasound
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS